Coultreon
Founded 2025 · 32 employees on LinkedIn · 10 known investors
Coultreon is a drug discovery and development company that advances small and large molecule therapeutic programmes across various disease areas, combining disease biology expertise with technology platforms.
Founders & leadership
PR
Pierre RaboissonChief Executive Officer Chief Scientific Officer Co-founder
MD
Marie De VulderChief Legal Officer Co-founder
GP
Guy PeetersChief Financial Officer Co-founder
JG
John-Paul GallivanHead of Development Co-founder
FK
Fabrice KolbHead of Immunology Co-founder
PP
Pieter PeetersOperating & Technology Officer Co-founder
FG
François GonzalvezCo-founder
SV
Sandrine VendevilleCo-founder
JK
Joost KolkmanCo-founder
Investors · 10
Longwood FundBoston
Sofinnova VenturesMenlo Park · $100K – $15M
BAM ElevatereportedChicago
Finchley Healthcare VenturesreportedMontreal
Forbionreported · 2 sourcesNaarden
Luma GroupreportedNew York
Novo Holdingsreported · 2 sourcesCopenhagen · $1.1M – $54M
Samsara BioCapitalreportedPalo Alto
Also in the syndicate · 2
GalapagosRegeneron Ventures
Funding
SEC filings, press & company announcements$125M disclosed across 1 round · 2026
- $125MSeries AApr 2026 · 3 sources
Sofinnova Investments (lead), Balyasny Asset Management, Finchley Healthcare Ventures, Forbion, Galapagos, Longwood Fund, Luma Group, Novo Holdings, Regeneron Ventures, Samsara BioCapital
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Competitors · 2
by search overlapBioworld3 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Day One Biopharmaceuticals3 shared keywordsDay One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors. Founded in 2018, it received its first FDA approval in 2024 for a pediatric brain tumor treatment.
Companies competing with Coultreon for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Coultreon do?
- Coultreon is a drug discovery and development company that advances small and large molecule therapeutic programmes across various disease areas, combining disease biology expertise with technology platforms.
- Who founded Coultreon?
- Coultreon was founded by Pierre Raboisson, Marie De Vulder, Guy Peeters, John-Paul Gallivan, Fabrice Kolb, Pieter Peeters, François Gonzalvez, Sandrine Vendeville, Joost Kolkman in 2025.
- Who are Coultreon's investors?
- Coultreon's investors include Longwood Fund, Sofinnova Ventures, BAM Elevate, Finchley Healthcare Ventures, Forbion, Luma Group, Novo Holdings, Samsara BioCapital.
- How much funding has Coultreon raised?
- Coultreon has disclosed $125M raised across 1 round.